Definition
A sympathomimetic agent with properties similar to DEXTROAMPHETAMINE. It is used in the treatment of obesity. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1222)
Description
A sympathomimetic agent with properties similar to dextroamphetamine. It is used in the treatment of obesity. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1222)
Top Gene Interactions
Related Pathways
General Information
- Metabolism: Hepatic. Benzphetamine's metabolites include amphetamine and methamphetamine. Half Life: 16 to 31 hours
- Uses/Sources: For the management of exogenous obesity as a short term adjunct (a few weeks) in a regimen of weight reduction based on caloric restriction
- Health Effects: Using large amounts of these drugs can result in a condition known as amphetamine psychosis -- which can result in auditory, visual and tactile hallucinations, intense paranoia, irrational thoughts and beliefs, delusions, and mental confusion.
- Symptoms: Acute overdosage may result in restlessness, tremor, tachypnea, confusion, assaultiveness, and panic states.
- Treatment: Management of acute amphetamine intoxication is largely symptomatic and includes sedation with a barbiturate. If hypertension is marked, the use of a nitrite or rapidly acting alpha receptor blocking agent should be considered. Acidification of the urine increases amphetamine excretion. (L1712)
- Route of Exposure: Oral. Readily absorbed from the gastro-intestinal tract and buccal mucosa. It Is resistant to metabolism by monoamine oxidase.
Toxicity
- Carcinogenicity: No indication of carcinogenicity to humans (not listed by IARC).
- Toxicity: LD50: 160 mg/kg (Oral, Rat) (A308)
Mechanism of Action
Target Name | Mechanism of Action | References |
---|---|---|
Sodium-dependent dopamine transporter Synaptic vesicular amine transporter |
15728379 7751968 15955613 |
|
Alpha-1A adrenergic receptor Alpha-2A adrenergic receptor NADPH--cytochrome P450 reductase |
Although the mechanism of action of the sympathomimetic appetite suppressants in the treatment of obesity is not fully known, these medications have pharmacological effects similar to those of amphetamines. Amphetamine and related sympathomimetic medications (such as benzphetamine) are thought to stimulate the release of norepinephrine and/or dopamine from storage sites in nerve terminals in the lateral hypothalamic feeding center, thereby producing a decrease in appetite. This release is mediated by the binding of benzphetamine to centrally located adrenergic receptors. |
17016423 3148724 3924914 3125159 17139284 2434473 1416971 |
Benzphetamine Interacts with Diseases
Disease | Inference Score | References/Inference Genes |
Gliosarcoma | 14.43 |
|
ANTLEY-BIXLER SYNDROME WITH GENITAL ANOMALIES AND DISORDERED STEROIDOGENESIS | 7.08 |
|
Prostatic Neoplasms | 6.86 |
|
Antley-Bixler Syndrome Phenotype | 6.53 |
|
Adrenal Hyperplasia, Congenital | 5.79 |
|
TOBACCO ADDICTION, SUSCEPTIBILITY TO | 5.74 |
|
Amenorrhea | 5.3 |
|
Alcoholic liver cirrhosis | 5.2 |
|
Fatty Liver, Alcoholic | 5.13 |
|
Alcohol dependence | 4.61 |
|
Hepatitis C | 4.61 |
|
Kidney Failure, Chronic | 4.58 |
|
Osteosarcoma | 4.44 |
|
Non-alcoholic fatty liver disease | 4.43 |
|
Lymphoma, Non-Hodgkin | 4.29 |
|
Learning Disorders | 4.28 |
|
Cell Transformation, Neoplastic | 4.26 |
|
Urinary Bladder Neoplasms | 4.23 |
|
Micronuclei, Chromosome-Defective | 4.19 |
|
Carcinoma, Non-Small-Cell Lung | 4.14 |
|